// App-Quantinova.ai

221 : Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Stephan A. Grupp

Principal Investigators

  • Jochen Buechner

  • Krysta Schlis

  • Paul L. Martin

  • Muna Qayed

  • Peter Bader

  • Hidefumi Hiramatsu

  • Francoise Mechinaud

  • Gregory A Yanik

  • Christina Peters

  • Andrea Biondi

  • Andre Baruchel

  • Henrique Bittencourt

  • Nicolas Boissel

  • Joerg Krueger

  • Carl H June

  • Kapildeb Sen

  • Yiyun Zhang

  • Karen E Thudium

  • Patricia A Wood

  • Tetiana Taran

  • Michael A Pulsipher

  • Shannon L Maude

  • Michael R. Verneris

  • Gary D Myers

  • Michael W Boyer

  • Susana Rives

  • Barbara De Moerloose

  • Eneida R. Nemecek

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • Children's Mercy Hospital and Clinics, Kansas City, MO

  • Division of Hematology, Oncology, and Blood and Marrow Transplantation, Childrens Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA

  • Hematology Oncology Division, CHU Sainte-Justine, Montreal, QC, Canada

  • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

  • Hematology, Hospital Saint Antoine, Paris, France,

  • Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Division of Oncology, Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA

  • Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

  • Pediatric Hematology,, Hopital Robert Debre, paris,

  • Cancer Research Institute Ghent (CRIG), Ghent, Belgium

  • Divison of Stem Cell Transplanation and Immunology, Hospital of Children and Adolescent of Frankfurt, Frankfurt, Germany

  • Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI

  • Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

  • University of Toronto, Toronto, ON, Canada

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Pediatric Hematology/Oncology & Bone Marrow Transplantation, Oregon Health & Science University, Portland, OR

  • Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, NC

  • Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, UT

  • Division of Paediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

  • Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

  • Center for Childhood Cancer Research, Childrens Hospital of Philadelphia, Philadelphia, PA

  • Children's Cancer Centre, The Royal Children's Hospital Melbourne, Melbourne, Australia

  • Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

  • Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, QC, Canada

  • Hospital for Sick Children, Toronto, ON, Canada

  • Paris, France

  • Stem Cell Transplantation Unit, St. Anna Childrens Hospital & EBMT-PDWP, Vienna, Austria

  • Department of Clinical Biostatistics, Graduate School of Medicine Kyoto University, Kyoto, Japan

  • Pauline Allen Gill Center for Cancer and Blood Disorders, Children's Health, Dallas, TX

  • Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, San Gerardo Hospital/Fondazione MBBM, Monza, Italy

Locations

  • Canada

  • Japan

  • Norway

  • Austria

  • Italy

  • Spain

  • Germany

  • Australia

  • United States

  • France

  • Belgium

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 19

  • Coxsackie Virus And Adenovirus Receptor

  • Glomeruloid microvascular proliferation

  • Twist-related protein 1

Drug/Treatment

  • CTL019

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved